Nebulized AER101 in Pre-op NSCLC
Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-100
SponsorUniversity of Oklahoma
About this trial
The primary objective of this pilot study is to determine if AER101 can decrease glycolysis in non-small cell lung cancer (NSCLC). Glycolysis is the process cells use to break down sugar (glucose) into a smaller substance in the fluid part inside the cell. Many lung cancers begin in bronchi, bronchioles and alveoli cells surrounding the airways, which enables nebulization to deposit AER101 on lung tumors.
Participants in the study will self-administer AER101 via a hand-held personal nebulizer three times per day (dosing at least 4 hours apart) for 14 days prior to undergoing surgery for lung cancer.
Eligibility criteria
Qualifiers
18 years or older
Agree to sign consent and follow study requirements
Recently diagnosed with lung adenocarcinoma or squamous cell carcinoma
Primary patients prior to resection
Disqualifiers
Recurrent tumor(s)
Nodal or metastatic tumor (multiple lung tumors are acceptable)
Pregnant patients
Patients unable to provide informed consent
Trial design
Treatments tested in this trial
- AER101
Treatment groups
5 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov